Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Quanta Services Inc. Stock Rallies 9.4%, Outperforms Peers

Quanta Services Inc. Stock Rallies 9.4%, Outperforms Peers

Dow JonesDow Jones2026/11/09 21:34

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Quanta Services Inc. rose 9.4% to $591.48 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 2.3% to 7,549.94 and the Dow Jones Industrial Average rising 2.2% to 52,389.75.

This was the stock's second consecutive day of gains.

Quanta Services Inc. closed 25.0% short of its 52-week high of $788.75, which the company achieved on May 6th.

The stock outperformed some of its peers, as AECOM rose 5.2% to $70.21, MasTec Inc. rose 8.6% to $189.05, and EMCOR Group Inc. rose 7.30% to $652.89.

Trading volume totaled 1.9 million, compared to the 50-day average of 1.2 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

November 09, 2026 16:34 ET (21:34 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12